rxsight inc. - RXST
RXST
Close Chg Chg %
26.56 -1.31 -4.93%
Closed Market
25.25
-1.31 (4.93%)
Volume: 682.06K
Last Updated:
Mar 31, 2025, 4:00 PM EDT
Company Overview: rxsight inc. - RXST
RXST Key Data
| Open $26.03 | Day Range 25.01 - 26.13 |
| 52 Week Range 24.09 - 66.54 | Market Cap $1.08B |
| Shares Outstanding 40.49M | Public Float 38.39M |
| Beta 1.22 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$0.71 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 559.23K |
RXST Performance
| 1 Week | -4.93% | ||
| 1 Month | -10.97% | ||
| 3 Months | -26.56% | ||
| 1 Year | -51.05% | ||
| 5 Years | N/A |
RXST Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
10
Full Ratings ➔
About rxsight inc. - RXST
RxSight, Inc. engages in the research, development, manufacture, and sale of light adjustable lenses and related capital equipment. It also commercializes adjustable intraocular lens (IOL) that is customized after cataract surgery. The company was founded on March 5, 1997 and is headquartered in Aliso Viejo, CA.
RXST At a Glance
RxSight, Inc.
100 Columbia
Aliso Viejo, California 92656
| Phone | 1-949-521-7830 | Revenue | 139.93M | |
| Industry | Electronic Components | Net Income | -27,455,000.00 | |
| Sector | Electronic Technology | 2024 Sales Growth | 57.085% | |
| Fiscal Year-end | 12 / 2025 | Employees | 498 | |
| View SEC Filings |
RXST Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 9.55 |
| Price to Book Ratio | 4.942 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -33.44 |
| Enterprise Value to Sales | 7.942 |
| Total Debt to Enterprise Value | 0.011 |
RXST Efficiency
| Revenue/Employee | 280,977.912 |
| Income Per Employee | -55,130.522 |
| Receivables Turnover | 4.656 |
| Total Asset Turnover | 0.555 |
RXST Liquidity
| Current Ratio | 11.355 |
| Quick Ratio | 10.504 |
| Cash Ratio | 9.168 |
RXST Profitability
| Gross Margin | 70.71 |
| Operating Margin | -26.341 |
| Pretax Margin | -19.585 |
| Net Margin | -19.621 |
| Return on Assets | -10.895 |
| Return on Equity | -12.434 |
| Return on Total Capital | -9.353 |
| Return on Invested Capital | -12.091 |
RXST Capital Structure
| Total Debt to Total Equity | 4.372 |
| Total Debt to Total Capital | 4.189 |
| Total Debt to Total Assets | 3.826 |
| Long-Term Debt to Equity | 4.026 |
| Long-Term Debt to Total Capital | 3.857 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Rxsight Inc. - RXST
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 22.59M | 49.01M | 89.08M | 139.93M | |
Sales Growth
| +53.92% | +116.90% | +81.77% | +57.09% | |
Cost of Goods Sold (COGS) incl D&A
| 18.08M | 27.68M | 35.31M | 40.98M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 3.99M | 4.02M | 4.24M | 3.62M | |
Depreciation
| 3.99M | 4.02M | 4.24M | 3.62M | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| +39.34% | +53.11% | +27.59% | +16.06% | |
Gross Income
| 4.52M | 21.33M | 53.77M | 98.94M | |
Gross Income Growth
| +164.93% | +372.17% | +152.09% | +84.03% | |
Gross Profit Margin
| +19.99% | +43.52% | +60.36% | +70.71% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 57.30M | 84.65M | 103.85M | 135.80M | |
Research & Development
| 24.50M | 25.98M | 29.05M | 34.37M | |
Other SG&A
| 32.80M | 58.66M | 74.80M | 101.43M | |
SGA Growth
| +54.42% | +47.71% | +22.69% | +30.77% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | (2.72M) | 1.77M | - |
EBIT after Unusual Expense
| (50.07M) | (63.32M) | (51.85M) | (36.86M) | |
Non Operating Income/Expense
| 5.07M | 1.52M | 6.57M | 9.47M | |
Non-Operating Interest Income
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 3.68M | 4.95M | 3.31M | 21.00K | |
Interest Expense Growth
| +621.96% | +34.33% | -33.12% | -99.37% | |
Gross Interest Expense
| 3.68M | 4.95M | 3.31M | 21.00K | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (48.68M) | (66.75M) | (48.59M) | (27.41M) | |
Pretax Income Growth
| -276.17% | -37.11% | +27.21% | +43.60% | |
Pretax Margin
| -215.46% | -136.20% | -54.55% | -19.59% | |
Income Tax
| 8.00K | 9.00K | 20.00K | 50.00K | |
Income Tax - Current - Domestic
| 13.20M | 14.92M | 12.81M | 19.15M | |
Income Tax - Current - Foreign
| 1.00K | 1.00K | (1.00K) | 1.00K | |
Income Tax - Deferred - Domestic
| (13.19M) | (14.91M) | (12.79M) | (19.10M) | |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (48.69M) | (66.76M) | (48.61M) | (27.45M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (48.69M) | (66.76M) | (48.61M) | (27.45M) | |
Net Income Growth
| -276.57% | -37.11% | +27.19% | +43.52% | |
Net Margin Growth
| -215.50% | -136.22% | -54.57% | -19.62% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (48.69M) | (66.76M) | (48.61M) | (27.45M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (48.69M) | (66.76M) | (48.61M) | (27.45M) | |
EPS (Basic)
| -1.7791 | -2.4133 | -1.4108 | -0.7064 | |
EPS (Basic) Growth
| -1,560.67% | -35.65% | +41.54% | +49.93% | |
Basic Shares Outstanding
| 27.37M | 27.66M | 34.46M | 38.87M | |
EPS (Diluted)
| -1.7791 | -2.4133 | -1.4108 | -0.7064 | |
EPS (Diluted) Growth
| -1,560.67% | -35.65% | +41.54% | +49.93% | |
Diluted Shares Outstanding
| 27.37M | 27.66M | 34.46M | 38.87M | |
EBITDA
| (48.80M) | (59.30M) | (45.84M) | (33.23M) | |
EBITDA Growth
| -55.45% | -21.51% | +22.69% | +27.50% | |
EBITDA Margin
| -215.99% | -121.00% | -51.46% | -23.75% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 44.30 | |
| Number of Ratings | 10 | Current Quarters Estimate | -0.123 | |
| FY Report Date | 06 / 2025 | Current Year's Estimate | -0.531 | |
| Last Quarter’s Earnings | -0.19 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -0.71 | Next Fiscal Year Estimate | -0.272 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 9 | 9 | 9 | 9 |
| Mean Estimate | -0.12 | -0.14 | -0.53 | -0.27 |
| High Estimates | -0.06 | -0.08 | -0.34 | -0.03 |
| Low Estimate | -0.18 | -0.19 | -0.72 | -0.50 |
| Coefficient of Variance | -33.01 | -25.09 | -22.02 | -64.92 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 8 | 8 | 8 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 2 | 2 | 2 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Rxsight Inc. - RXST
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Rxsight Inc. - RXST
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Mar 14, 2025 | Tamara R. Fountain Director | 24,793 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $25.71 per share | 637,428.03 |
| Feb 28, 2025 | Shelley B. Thunen See remarks | 125,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 28, 2025 | Eric Weinberg See remarks | 125,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 28, 2025 | Ronald M. Kurtz President & CEO; Director | 215,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 28, 2025 | Ilya Goldshleger See remarks | 125,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jul 17, 2024 | Shelley B. Thunen See remarks | 6,405 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jul 17, 2024 | Shelley B. Thunen See remarks | 1,387 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jul 3, 2024 | Shelley B. Thunen Chief Financial Officer | 1,803 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $58.55 per share | 105,565.65 |
| Jul 3, 2024 | Shelley B. Thunen Chief Financial Officer | N/A | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $59.56 per share | 0.00 |
| Jul 3, 2024 | Shelley B. Thunen Chief Financial Officer | 36,805 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jun 18, 2024 | Julie B. Andrews Director | 33,972 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $57.84 per share | 1,964,940.48 |
| Jun 18, 2024 | Julie B. Andrews Director | 30,287 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $58.53 per share | 1,772,698.11 |
| Jun 11, 2024 | J. Andrew Corley Director | 32,643 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 11, 2024 | Shweta Singh Maniar Director | 14,684 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 11, 2024 | Robert K. Warner Director | 30,287 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 11, 2024 | Juliet Tammenoms Bakker Director | 37,394 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 11, 2024 | Robert J. Palmisano Director | 30,287 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 11, 2024 | William J. Link Director | 27,103 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 21, 2024 | Ilya Goldshleger Chief Operating Officer | 46,982 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $4.13 per share | 194,035.66 |
| May 21, 2024 | Ilya Goldshleger Chief Operating Officer | 51,246 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $4.34 per share | 222,407.64 |